Role of Surgery in T4N0-3M0 Esophageal Cancer

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2023 Nov 26

PMID 38008742

Authors

Chen Qi

Liwen Hu

Chi Zhang

Kang Wang

Bingmei Qiu

Jun Yi

Yi Shen

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate an unsettled issue that whether T4 esophageal cancer could benefit from surgery.

Methods: Patients with T4N0-3M0 esophageal cancer from 2004 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were included in this study. Kaplan-Meier method, Cox proportional hazard regression, and propensity score matching (PSM) were used to compare overall survival (OS) between the surgery and no-surgery group.

Results: A total of 1822 patients were analyzed. The multivariable Cox regression showed the HR (95% CI) for surgery vs. no surgery was 0.492 (0.427-0.567) (P < 0.001) in T4N0-3M0 cohort, 0.471 (0.354-0.627) (P < 0.001) in T4aN0-3M0 cohort, and 0.480 (0.335-0.689) (P < 0.001) in T4bN0-3M0 cohort. The HR (95% CI) for neoadjuvant therapy plus surgery vs. no surgery and surgery without neoadjuvant therapy vs. no surgery were 0.548 (0.461-0.650) (P < 0.001) and 0.464 (0.375-0.574) (P < 0.001), respectively. No significant OS difference was observed between neoadjuvant therapy plus surgery and surgery without neoadjuvant therapy: 0.966 (0.686-1.360) (P = 0.843). Subgroup analyses and PSM-adjusted analyses showed consistent results.

Conclusion: Surgery might bring OS improvement for T4N0-3M0 esophageal cancer patients, no matter in T4a disease or in T4b disease. Surgery with and without neoadjuvant therapy might both achieve better OS than no surgery.

References

Shimoji H, Karimata H, Nagahama M, Nishimaki T . Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013; 37(9):2180-8. DOI: 10.1007/s00268-013-2074-x. View

Gao L, Li C, Han W, Ni W, Deng W, Tan L . Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy. Ther Adv Med Oncol. 2022; 14:17588359221108693. PMC: 9340417. DOI: 10.1177/17588359221108693. View

Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S . Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999; 17(9):2915-21. DOI: 10.1200/JCO.1999.17.9.2915. View

Loftus T, Tighe P, Filiberto A, Efron P, Brakenridge S, Mohr A . Artificial Intelligence and Surgical Decision-making. JAMA Surg. 2019; 155(2):148-158. PMC: 7286802. DOI: 10.1001/jamasurg.2019.4917. View

Yamaguchi S, Morita M, Yamamoto M, Egashira A, Kawano H, Kinjo N . Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion. Ann Surg Oncol. 2018; 25(11):3280-3287. DOI: 10.1245/s10434-018-6656-6. View

He H, Chen N, Hou Y, Wang Z, Zhang Y, Zhang G . Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis. Thorac Cancer. 2020; 11(5):1121-1128. PMC: 7180574. DOI: 10.1111/1759-7714.13311. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Makino T, Yamasaki M, Tanaka K, Tatsumi M, Takiguchi S, Hatazawa J . Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery. 2017; 162(4):836-845. DOI: 10.1016/j.surg.2017.06.007. View

Takakusagi Y, Kano K, Shima S, Tsuchida K, Mizoguchi N, Katoh H . Clinical Outcomes of Radiotherapy in Elderly and Younger Patients With T4 Esophageal Cancer: A Retrospective Single-center Analysis. Anticancer Res. 2022; 42(4):2095-2104. DOI: 10.21873/anticanres.15691. View

10.

Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y . Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenterol Surg. 2019; 3(2):169-180. PMC: 6422802. DOI: 10.1002/ags3.12222. View

11.

Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L . Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial. JAMA Oncol. 2021; 7(10):1459-1466. PMC: 8343504. DOI: 10.1001/jamaoncol.2021.2705. View

12.

Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge Henegouwen M, Wijnhoven B . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. View

13.

Chadebecq F, Lovat L, Stoyanov D . Artificial intelligence and automation in endoscopy and surgery. Nat Rev Gastroenterol Hepatol. 2022; 20(3):171-182. DOI: 10.1038/s41575-022-00701-y. View

14.

Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T . A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016; 78(1):91-9. PMC: 4921115. DOI: 10.1007/s00280-016-3062-2. View

15.

Shimada H, Shiratori T, Okazumi S, Matsubara H, Nabeya Y, Shuto K . Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg. 2007; 206(1):48-56. DOI: 10.1016/j.jamcollsurg.2007.06.013. View

16.

Gamliel Z, Krasna M . Multimodality treatment of esophageal cancer. Surg Clin North Am. 2005; 85(3):621-30. DOI: 10.1016/j.suc.2005.01.011. View

17.

Akutsu Y, Matsubara H . Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. Surg Today. 2015; 45(11):1360-5. DOI: 10.1007/s00595-015-1116-4. View

18.

Rice T, Patil D, Blackstone E . 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017; 6(2):119-130. PMC: 5387145. DOI: 10.21037/acs.2017.03.14. View

19.

Cooper J, Guo M, Herskovic A, Macdonald J, Martenson Jr J, Al-Sarraf M . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281(17):1623-7. DOI: 10.1001/jama.281.17.1623. View

20.

Akutsu Y, Kono T, Uesato M, Hoshino I, Murakami K, Aoyagi T . Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor?. World J Surg. 2014; 38(11):2891-7. DOI: 10.1007/s00268-014-2668-y. View